MX2024011667A - Inmunosupresion especifica de mielina mediada por el mhc ib como un nuevo tratamiento para la esclerosis multiple y la enfermedad por anticuerpos mog. - Google Patents

Inmunosupresion especifica de mielina mediada por el mhc ib como un nuevo tratamiento para la esclerosis multiple y la enfermedad por anticuerpos mog.

Info

Publication number
MX2024011667A
MX2024011667A MX2024011667A MX2024011667A MX2024011667A MX 2024011667 A MX2024011667 A MX 2024011667A MX 2024011667 A MX2024011667 A MX 2024011667A MX 2024011667 A MX2024011667 A MX 2024011667A MX 2024011667 A MX2024011667 A MX 2024011667A
Authority
MX
Mexico
Prior art keywords
multiple sclerosis
mog antibody
mho
novel treatment
antibody disease
Prior art date
Application number
MX2024011667A
Other languages
English (en)
Spanish (es)
Inventor
Valentin Bruttel
Jörg Wischhusen
Daniela Brünnert
Fadhil Ahsan
Original Assignee
Univ Wuerzburg J Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wuerzburg J Maximilians filed Critical Univ Wuerzburg J Maximilians
Publication of MX2024011667A publication Critical patent/MX2024011667A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2024011667A 2022-03-24 2023-03-24 Inmunosupresion especifica de mielina mediada por el mhc ib como un nuevo tratamiento para la esclerosis multiple y la enfermedad por anticuerpos mog. MX2024011667A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22164122 2022-03-24
PCT/EP2023/057679 WO2023180546A1 (en) 2022-03-24 2023-03-24 Mho ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease

Publications (1)

Publication Number Publication Date
MX2024011667A true MX2024011667A (es) 2024-09-27

Family

ID=81389016

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011667A MX2024011667A (es) 2022-03-24 2023-03-24 Inmunosupresion especifica de mielina mediada por el mhc ib como un nuevo tratamiento para la esclerosis multiple y la enfermedad por anticuerpos mog.

Country Status (12)

Country Link
US (1) US20250222083A1 (https=)
EP (1) EP4499676A1 (https=)
JP (1) JP2025513720A (https=)
KR (1) KR20240162578A (https=)
CN (1) CN118922435A (https=)
AU (1) AU2023240382A1 (https=)
CA (1) CA3255287A1 (https=)
CL (1) CL2024002837A1 (https=)
CO (1) CO2024013220A2 (https=)
IL (1) IL315510A (https=)
MX (1) MX2024011667A (https=)
WO (1) WO2023180546A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025061913A1 (en) * 2023-09-22 2025-03-27 Julius-Maximilians-Universität Würzburg Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630809A1 (en) 2017-05-23 2020-04-08 Bruttel, Valentin Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
US11464840B2 (en) * 2018-02-26 2022-10-11 Swey-Shen Chen Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers

Also Published As

Publication number Publication date
US20250222083A1 (en) 2025-07-10
CL2024002837A1 (es) 2025-02-21
EP4499676A1 (en) 2025-02-05
AU2023240382A1 (en) 2024-11-14
CO2024013220A2 (es) 2024-10-31
CA3255287A1 (en) 2023-09-28
CN118922435A (zh) 2024-11-08
KR20240162578A (ko) 2024-11-15
WO2023180546A1 (en) 2023-09-28
IL315510A (en) 2024-11-01
WO2023180546A8 (en) 2024-10-17
JP2025513720A (ja) 2025-04-30

Similar Documents

Publication Publication Date Title
CO2024013220A2 (es) Inmunosupresión específica de mielina mediada por el mhc ib como un nuevo tratamiento para la esclerosis múltiple y la enfermedad por anticuerpos mog
PE20250839A1 (es) Proteinas y conjugados de union al receptor de transferrina
BR112022019609A2 (pt) Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas
CR8131A (es) Peptidos novedosos que se unen al receptor de la eritropoyetina
MX2021000401A (es) Nuevas proteinas de fusion especificas para cd137 y pd-l1.
BRPI0607326A2 (pt) composição de vacina, variante de peptìdeo de survivina, uso da referida composição, kit em partes e medicamento
CL2024001738A1 (es) Vacunas peptídicas
CO2020013221A2 (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos
CO2022018347A2 (es) Cisteína proteasa
CO2021016487A2 (es) Vectores aav con el promotor de la proteína cero de mielina y usos de los mismos para el tratamiento de enfermedades asociadas a las células de schwann como la enfermedad de charcot-marie-tooth
MX2022001682A (es) Nuevos formatos de moleculas de union a antigenos.
CO2024012329A2 (es) Inducción de tolerancia específica de alfa-sinucleína mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson
CO2024012332A2 (es) Inmunosupresión específica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo
CO2024003578A2 (es) Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos
MX2022005345A (es) Terapia de combinación para el tratamiento de cáncer cerebral.
CO2026004947A2 (es) Proteínas de unión al receptor de transferrina y usos de estas
CO2025009946A2 (es) Proteínas de unión al antígeno anti-tnfr2 y sus usos
BR112021021210A2 (pt) Conjunto de polipeptídeos, método para gerar um polipeptídeo heterodimérico, primeiro polipeptídeo precursor heterodimérico, segundo polipeptídeo precursor heterodimérico e composição farmacêutica
CO2025011125A2 (es) Conjugados anticuerpo-fármaco anti-cd70
CO2024012945A2 (es) Inmunosupresión específica del antígeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1
AR051928A1 (es) Peptidos y derivados tipo apl de la hsp60 y composiciones farmaceuticas
MX2024014378A (es) Proteinas de fusion que comprenden un agonista mejorado del receptor glp-1 y sus usos
CL2023001183A1 (es) Proteínas de fusión para el tratamiento de enfermedades
MX2021009767A (es) Moleculas de union de fmcr y usos de las mismas.
AR133775A1 (es) Composiciones de arn para administración de agentes incretina